Effect of renal artery stenting on left ventricular mass: A randomized clinical trial

American Journal of Kidney Diseases

Volumn 60, Issue 1, 2012, Pages 39-46

  Marcantoni, Carmelita ^a   Zanoli, Luca ^b   Rastelli, Stefania ^b   Tripepi, Giovanni ^c   Matalone, Massimo ^a   Mangiafico, Sarah ^b   Capodanno, Davide ^b   Scandura, Salvatore ^b   Di Landro, Domenico ^a   Tamburino, Corrado ^b   Zoccali, Carmine ^c   Castellino, Pietro ^b  

^a CANNIZZARO HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

coronary artery disease; left ventricular hypertrophy; Renal artery stenosis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY ATENTING; SINGLE BLIND PROCEDURE; STENT; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOPLASTY, BALLOON; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RENAL ARTERY OBSTRUCTION; STENTS;

EID: 84862626181     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.01.022     Document Type: Article

References (28)

1. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patient undergoing coronary angiography. Kidney Int. 2001;60:1490-1497.
2. Wright JR, Shurrab AE, Cooper A, Kalra PR, Foley RN, Kalra PA. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol. 2005;16:2746-2753.
3. Zoccali C, Mallamaci F, Finocchiaro P. Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. J Am Soc Nephrol. 2002;13(suppl 3):S179-S183.
4. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12:1079-1084.
5. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759-2767.
6. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65(4):1492-1498.
7. Zhang R, Crump J, Reisin E. Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Rep. 2003;5:301-308.
8. ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953-1962.
9. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. Circulation. 2002;106:1572-1585.
10. Fraker TD Jr, Fihn SD, Gibbons RJ, et al; on behalf of the 2002 Chronic Stable Angina Writing Committee. Management of Patients With Chronic Stable Angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesWriting Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Circulation. 2007;116:2762-2772.
11. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
12. Gottdiener JS, Bednarz J, Devereux R, et al. Recommendations for use of echocardiography in clinical trials: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Echocardiography in Clinical Trials. J Am Soc Echocardiogr. 2004;17:1086-1119.
13. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
14. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double blind studies until December 1996). Nephrol Dial Transplant. 1998;13:564-569.
15. Marcantoni C, Rastelli S, Zanoli L, et al. Prevalence of renal artery stenosis in patients undergoing cardiac catheterization [published online ahead of print June 26, 2011]. Intern Emerg Med. doi:10.1007/s11739-011-0657-9.
16. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone producing adenoma, and pheochromocytoma. Am J Hypertens. 1993;6:907-913.
17. Symonides B. Effects of the correction of renal artery stenosis on blood pressure, renal function and left ventricular morphology. Blood Press. 1999;8:141-150.
18. Corriere MA, Hoyle JR, Craven TE, et al. Changes in left ventricular structure and function following renal artery revascularization. Ann Vasc Surg. 2010;24(1):80-84.
19. Zeller T, Rastan A, Schwarzwälder U, et al. Regression of left ventricular hypertrophy following stenting of renal artery stenosis. J Endovasc Ther. 2007;14:189-197.
20. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995- 1003.
21. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374(9689):525-533.
22. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16(11, pt 1):895-899.
23. Dworkin LD, Muphy T. Is there any reason to stent atherosclerotic renal artery stenosis. Am J Kidney Dis. 2010;56:259-263.
24. Mangiacapra F, Trana C, Sarno G, et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc Interv. 2010;3(6):537-542.
25. De Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009;27:1333-1340.
26. El-Mawardy RH, Ghareeb MA, Mahdy MM, Sabet SS, Nammas WM. Prevalence and predictors of renal artery stenosis in hypertensive patients undergoing elective coronary procedures. J Clin Hypertens. 2008;10:844-849.
27. Przewlocki T, Kablak-Ziembicka A, Tracz W, et al. Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease. Nephrol Dial Transplant. 2008;23:580-585.
28. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152:59-66.